Zentalis Pharmaceuticals (NASDAQ:ZNTL) Coverage Initiated at Rodman & Renshaw

Stock analysts at Rodman & Renshaw began coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm set a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw’s price target would indicate a potential upside of 154.04% from the stock’s current price.

ZNTL has been the subject of a number of other research reports. Guggenheim lifted their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Mizuho started coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $6.75.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $4.33 on Thursday. Zentalis Pharmaceuticals has a 1-year low of $1.21 and a 1-year high of $6.95. The company has a market capitalization of $308.25 million, a PE ratio of -2.50 and a beta of 1.92. The business has a 50-day moving average of $4.15 and a 200-day moving average of $3.47.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, equities analysts expect that Zentalis Pharmaceuticals will post -1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. 5AM Venture Management LLC raised its stake in Zentalis Pharmaceuticals by 705.7% during the fourth quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after acquiring an additional 3,457,913 shares during the period. Millennium Management LLC boosted its stake in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after acquiring an additional 2,111,951 shares during the period. Ishara Investments LP acquired a new position in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $1,782,000. Opaleye Management Inc. grew its holdings in shares of Zentalis Pharmaceuticals by 342.6% during the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock valued at $1,891,000 after purchasing an additional 1,084,356 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $1,126,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.